AN2 Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 21

Employees

  • Stock Symbol
  • ANTX

Stock Symbol

  • Share Price
  • $5.10
  • (As of Friday Closing)

AN2 Therapeutics General Information

Description

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1300 El Camino Real
  • Suite 100
  • Menlo Park, CA 94025
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1300 El Camino Real
  • Suite 100
  • Menlo Park, CA 94025
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AN2 Therapeutics Stock Performance

As of 20-Nov-2026, AN2 Therapeutics’s stock price is $5.10. Its current market cap is $193M with 37.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.10 $5.22 $1.00 - $7.19 $193M 37.9M 288K -$0.92

AN2 Therapeutics Financials Summary

As of 30-Sep-2026, AN2 Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 122,370 (30,683) (52,193) 485,584
Revenue 0 0 0 0
EBITDA (37,441) (38,108) (56,787) (69,592)
Net Income (34,880) (35,174) (51,321) (64,732)
Total Assets 81,955 61,950 92,087 138,744
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AN2 Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AN2 Therapeutics‘s full profile, request access.

Request a free trial

AN2 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore AN2 Therapeutics‘s full profile, request access.

Request a free trial

AN2 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeut
Drug Discovery
Menlo Park, CA
21 As of 2026

Cambridge, MA
 

Eindhoven, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AN2 Therapeutics Competitors (6)

One of AN2 Therapeutics’s 6 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spero Therapeutics Formerly VC-backed Cambridge, MA
Ambagon Therapeutics Venture Capital-Backed Eindhoven, Netherlands
VLP Therapeutics Venture Capital-Backed Gaithersburg, MD
RedHill Biopharma Formerly VC-backed Raleigh, NC
BITT (Drug Discovery) Venture Capital-Backed Boston, MA
To view AN2 Therapeutics’s complete competitors history, request access »

AN2 Therapeutics Patents

AN2 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236678-A1 Boron heterocycle containing compounds as enpp inhibitors, and uses thereof Pending 09-May-2025
WO-2026080526-A1 Boron heterocycle containing compounds and uses thereof Pending 08-Oct-2024
WO-2026060334-A1 Boron heterocycle containing compounds as enpp inhibitors and uses thereof Pending 13-Sep-2024
EP-4766704-A1 Chemical compounds Pending 30-Jun-2023
WO-2025007074-A9 Chemical compounds Inactive 30-Jun-2023 C07D405/04
To view AN2 Therapeutics’s complete patent history, request access »

AN2 Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AN2 Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AN2 Therapeutics‘s full profile, request access.

Request a free trial

AN2 Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.65 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view AN2 Therapeutics’s complete esg history, request access »

AN2 Therapeutics FAQs

  • When was AN2 Therapeutics founded?

    AN2 Therapeutics was founded in 2017.

  • Where is AN2 Therapeutics headquartered?

    AN2 Therapeutics is headquartered in Menlo Park, CA.

  • What is the size of AN2 Therapeutics?

    AN2 Therapeutics has 21 total employees.

  • What industry is AN2 Therapeutics in?

    AN2 Therapeutics’s primary industry is Drug Discovery.

  • Is AN2 Therapeutics a private or public company?

    AN2 Therapeutics is a Public company.

  • What is AN2 Therapeutics’s stock symbol?

    The ticker symbol for AN2 Therapeutics is ANTX.

  • What is the current stock price of AN2 Therapeutics?

    As of 20-Nov-2026 the stock price of AN2 Therapeutics is $5.10.

  • What is the current market cap of AN2 Therapeutics?

    The current market capitalization of AN2 Therapeutics is $193M.

  • Who are AN2 Therapeutics’s competitors?

    Spero Therapeutics, Ambagon Therapeutics, VLP Therapeutics, RedHill Biopharma, and BITT (Drug Discovery) are some of the 6 competitors of AN2 Therapeutics.

  • What is AN2 Therapeutics’s annual earnings per share (EPS)?

    AN2 Therapeutics’s EPS for 12 months was -$0.92.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process